Treatment outcome according to selected clinical and biological characteristics
| Variable . | No. of patients . | 5-y overall survival, % (95% CI) . | P . | 5-y event-free survival, % (95% CI) . | P . |
|---|---|---|---|---|---|
| Provisional risk group | |||||
| Low | 4748 | 95.2 (94.3-96.2) | <.001 | 85.1 (83.4-86.7) | <.001 |
| Intermediate | 2887 | 84.0 (81.9-86.1) | 72.1 (69.8-74.5) | ||
| High | 5 | 40.0 (13.7-100) | 40.0 (13.7-100) | ||
| Final risk group | |||||
| Low | 3948 | 96.3 (95.4-97.3) | <.001 | 87.9 (86.4-89.5) | <.001 |
| Intermediate | 3543 | 85.9 (84.1-87.8) | 72.6 (70.3-75.1) | ||
| High | 149 | 64.9 (55.7-75.7) | 41.7 (32.9-52.9) | ||
| Age at diagnosis, y | |||||
| <1 | 134 | 67.8 (59.1-77.8) | <.001 | 60.8 (51.1-72.3) | <.001 |
| 1-10 | 6481 | 92.6 (91.6-93.6) | 81.9 (80.5-83.4) | ||
| >10 | 1025 | 84.2 (80.9-87.7) | 72.1 (68.1-76.3) | ||
| Sex | |||||
| Male | 4521 | 90.4 (89.0-91.9) | .60 | 78.2 (76.4-80.1) | .005 |
| Female | 3119 | 92.1 (90.9-93.3) | 83.3 (81.3-85.3) | ||
| Leukocyte count, ×109/L | |||||
| <50 | 6026 | 93.5 (92.6-94.4) | <.001 | 83.1 (81.6-84.6) | <.001 |
| ≥50 | 1614 | 81.7 (78.3-85.1) | 69.4 (66.2-72.7) | ||
| CNS status | |||||
| CNS1 | 7074 | 91.5 (90.5-92.5) | <.001 | 80.8 (79.4-82.2) | <.001 |
| CNS2 | 116 | 81.8 (73.3-91.2) | 57.2 (42.8-76.4) | ||
| Traumatic lumbar puncture | 374 | 90.0 (86.5-93.6) | 79.9 (72.4-88.3) | ||
| CNS3 | 76 | 78.4 (68.4-90.0) | 67.4 (56.3-80.6) | ||
| Immunophenotype | |||||
| B-lineage | 6916 | 92.1 (91.2-93.0) | <.001 | 80.9 (79.4-82.4) | <.001 |
| T-lineage | 724 | 81.0 (75.7-86.6) | 74.4 (70.7-78.4) | ||
| Ploidy | |||||
| Hyperdiploidy >50 | 1059 | 94.2 (92.3-96.1) | <.001 | 82.2 (78.6-86.0) | <.001 |
| Others | 6581 | 90.6 (89.5-91.7) | 80.0 (78.5-81.5) | ||
| t(9;22)(BCR-ABL1) | |||||
| Present | 335 | 77.6 (69.4-86.8) | <.001 | 52.1 (43.1-62.9) | <.001 |
| Absent | 7305 | 91.7 (90.7-92.6) | 81.4 (80.0-82.8) | ||
| KMT2A rearrangement | |||||
| Present | 260 | 73.6 (67.0-80.8) | <.001 | 58.6 (51.6-66.5) | <.001 |
| Absent | 7380 | 91.7 (90.7-92.7) | 81.0 (79.6-82.4) | ||
| t(1;19)(TCF3-PBX1) | |||||
| Present | 384 | 89.3 (85.0-93.9) | .10 | 84.7 (80.7-88.9) | 0.80 |
| Absent | 7256 | 91.2 (90.2-92.2) | 80.1 (78.7-81.6) | ||
| t(12;21)(ETV6-RUNX1) | |||||
| Present | 1452 | 97.0 (95.2-98.8) | <.001 | 88.7 (85.7-91.8) | <.001 |
| Absent | 6188 | 89.7 (88.6-90.8) | 78.2 (76.7-79.8) | ||
| MRD on day 19 of induction, % | |||||
| <0.01 | 3497 | 95.3 (94.1-96.5) | <.001 | 88.7 (87.2-90.3) | <.001 |
| 0.01-0.09 | 1084 | 92.8 (90.5-95.1) | 84.8 (82.0-87.7) | ||
| 0.1-0.99 | 1433 | 89.5 (86.9-92.1) | 72.9 (69.2-76.7) | ||
| ≥1 | 1370 | 83.5 (80.7-86.3) | 65.0 (60.9-69.3) | ||
| MRD on day 46 of induction, % | |||||
| <0.01 | 6116 | 94.3 (93.3-95.3) | <.001 | 84.8 (83.3-86.2) | <.001 |
| 0.01-0.09 | 525 | 86.4 (82.1-90.9) | 68.1 (62.2-74.6) | ||
| 0.1-0.99 | 296 | 78.5 (71.8-85.9) | 48.7 (41.0-57.9) | ||
| ≥1 | 144 | 66.1 (56.7-76.9) | 41.8 (32.9-53.2) |
| Variable . | No. of patients . | 5-y overall survival, % (95% CI) . | P . | 5-y event-free survival, % (95% CI) . | P . |
|---|---|---|---|---|---|
| Provisional risk group | |||||
| Low | 4748 | 95.2 (94.3-96.2) | <.001 | 85.1 (83.4-86.7) | <.001 |
| Intermediate | 2887 | 84.0 (81.9-86.1) | 72.1 (69.8-74.5) | ||
| High | 5 | 40.0 (13.7-100) | 40.0 (13.7-100) | ||
| Final risk group | |||||
| Low | 3948 | 96.3 (95.4-97.3) | <.001 | 87.9 (86.4-89.5) | <.001 |
| Intermediate | 3543 | 85.9 (84.1-87.8) | 72.6 (70.3-75.1) | ||
| High | 149 | 64.9 (55.7-75.7) | 41.7 (32.9-52.9) | ||
| Age at diagnosis, y | |||||
| <1 | 134 | 67.8 (59.1-77.8) | <.001 | 60.8 (51.1-72.3) | <.001 |
| 1-10 | 6481 | 92.6 (91.6-93.6) | 81.9 (80.5-83.4) | ||
| >10 | 1025 | 84.2 (80.9-87.7) | 72.1 (68.1-76.3) | ||
| Sex | |||||
| Male | 4521 | 90.4 (89.0-91.9) | .60 | 78.2 (76.4-80.1) | .005 |
| Female | 3119 | 92.1 (90.9-93.3) | 83.3 (81.3-85.3) | ||
| Leukocyte count, ×109/L | |||||
| <50 | 6026 | 93.5 (92.6-94.4) | <.001 | 83.1 (81.6-84.6) | <.001 |
| ≥50 | 1614 | 81.7 (78.3-85.1) | 69.4 (66.2-72.7) | ||
| CNS status | |||||
| CNS1 | 7074 | 91.5 (90.5-92.5) | <.001 | 80.8 (79.4-82.2) | <.001 |
| CNS2 | 116 | 81.8 (73.3-91.2) | 57.2 (42.8-76.4) | ||
| Traumatic lumbar puncture | 374 | 90.0 (86.5-93.6) | 79.9 (72.4-88.3) | ||
| CNS3 | 76 | 78.4 (68.4-90.0) | 67.4 (56.3-80.6) | ||
| Immunophenotype | |||||
| B-lineage | 6916 | 92.1 (91.2-93.0) | <.001 | 80.9 (79.4-82.4) | <.001 |
| T-lineage | 724 | 81.0 (75.7-86.6) | 74.4 (70.7-78.4) | ||
| Ploidy | |||||
| Hyperdiploidy >50 | 1059 | 94.2 (92.3-96.1) | <.001 | 82.2 (78.6-86.0) | <.001 |
| Others | 6581 | 90.6 (89.5-91.7) | 80.0 (78.5-81.5) | ||
| t(9;22)(BCR-ABL1) | |||||
| Present | 335 | 77.6 (69.4-86.8) | <.001 | 52.1 (43.1-62.9) | <.001 |
| Absent | 7305 | 91.7 (90.7-92.6) | 81.4 (80.0-82.8) | ||
| KMT2A rearrangement | |||||
| Present | 260 | 73.6 (67.0-80.8) | <.001 | 58.6 (51.6-66.5) | <.001 |
| Absent | 7380 | 91.7 (90.7-92.7) | 81.0 (79.6-82.4) | ||
| t(1;19)(TCF3-PBX1) | |||||
| Present | 384 | 89.3 (85.0-93.9) | .10 | 84.7 (80.7-88.9) | 0.80 |
| Absent | 7256 | 91.2 (90.2-92.2) | 80.1 (78.7-81.6) | ||
| t(12;21)(ETV6-RUNX1) | |||||
| Present | 1452 | 97.0 (95.2-98.8) | <.001 | 88.7 (85.7-91.8) | <.001 |
| Absent | 6188 | 89.7 (88.6-90.8) | 78.2 (76.7-79.8) | ||
| MRD on day 19 of induction, % | |||||
| <0.01 | 3497 | 95.3 (94.1-96.5) | <.001 | 88.7 (87.2-90.3) | <.001 |
| 0.01-0.09 | 1084 | 92.8 (90.5-95.1) | 84.8 (82.0-87.7) | ||
| 0.1-0.99 | 1433 | 89.5 (86.9-92.1) | 72.9 (69.2-76.7) | ||
| ≥1 | 1370 | 83.5 (80.7-86.3) | 65.0 (60.9-69.3) | ||
| MRD on day 46 of induction, % | |||||
| <0.01 | 6116 | 94.3 (93.3-95.3) | <.001 | 84.8 (83.3-86.2) | <.001 |
| 0.01-0.09 | 525 | 86.4 (82.1-90.9) | 68.1 (62.2-74.6) | ||
| 0.1-0.99 | 296 | 78.5 (71.8-85.9) | 48.7 (41.0-57.9) | ||
| ≥1 | 144 | 66.1 (56.7-76.9) | 41.8 (32.9-53.2) |